NCT06716970View on ClinicalTrials.gov

QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

810

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

February 28, 2027

Conditions
Essential Hypertension
Interventions
DRUG

QR12000 75mg

QR12000 75mg QD

DRUG

QR12000 75mg placebo

Matching placebo of QR12000 75mg QD

DRUG

QR12000 150mg

QR12000 150mg QD

DRUG

QR12000 150mg placebo

Matching placebo of QR12000 150mg QD

DRUG

Sacubitril/valsartan 200mg

Sacubitril/valsartan 200mg QD

DRUG

Sacubitril/valsartan 200mg placebo

Matching placebo of Sacubitril/valsartan 200mg QD

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Wuhan Createrna Science and Technology Co., Ltd

INDUSTRY